rethinkTHC Search
Menu
Study breakdown

CBD probably reduces seizures in children with drug-resistant epilepsy, systematic review confirms

Systematic ReviewStrong evidence
The takeaway

High-quality RCTs show cannabidiol reduces monthly seizure frequency by about 20% compared to placebo in children with drug-resistant epilepsy, though it does not significantly increase seizure freedom rates.

Parents of children with epilepsy, people interested in CBD medical evidence, and anyone following cannabis-based medicine.

CBD reduced monthly seizures by 19.8% vs placebo in drug-resistant pediatric epilepsy

What the researchers found

CBD reduced median monthly seizure frequency by 19.8% vs placebo (95% CI: -27.0% to -12.6%) and increased the proportion achieving 50%+ seizure reduction (RR = 1.76). However, seizure freedom was not significantly different. Diarrhea was significantly more common with CBD (RR = 2.25).

Why it matters

This provides the most rigorous assessment of CBD for pediatric epilepsy at the time of publication. The moderate-certainty evidence supports its use for drug-resistant cases, while clearly noting that results apply specifically to pharmaceutical-grade CBD, not all cannabis products.

The numbers in context

4 RCTs + 19 non-randomized studies. Seizure frequency reduction: -19.8% (95% CI: -27.0% to -12.6%). 50%+ seizure reduction: RR 1.76 (95% CI: 1.07-2.88). Diarrhea: RR 2.25 (95% CI: 1.38-3.68). No significant difference in seizure freedom, quality of life, or sleep.

How the study worked

Living systematic review with meta-analysis of 4 RCTs and 19 non-randomized studies. Searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature. Risk of bias assessed per study; GRADE used for quality of evidence per outcome.

What this study cannot tell us

All non-randomized studies were at high risk of bias. Evidence is primarily limited to pharmaceutical-grade CBD. Quality of life and sleep outcomes showed no significant improvement. Short follow-up periods in most studies.

How to read the evidence

Strong: systematic review with meta-analysis including 4 low-risk-of-bias RCTs and GRADE quality assessment.

When this study was published

Published in 2019.

The bigger picture

This review arrived as CBD products were flooding consumer markets with epilepsy claims. The evidence specifically supports pharmaceutical-grade cannabidiol for specific severe epilepsies, not broad use of unregulated CBD products for seizure disorders.

Questions still open

  • Would longer treatment periods show improvements in quality of life and sleep? Does CBD work for epilepsy types beyond Dravet and Lennox-Gastaut syndromes? How much of the seizure benefit is attributable to CBD's interaction with clobazam rather than direct effects?

Common questions

Does CBD help children with epilepsy?
Pharmaceutical-grade CBD reduced monthly seizure frequency by about 20% compared to placebo in children with drug-resistant epilepsy, based on high-quality clinical trial data. It did not achieve complete seizure freedom.
Can any CBD product be used for epilepsy?
The evidence specifically supports pharmaceutical-grade cannabidiol (like Epidiolex). The authors explicitly warn against extending these findings to all cannabis-based products, which vary widely in composition and quality.

Read the original research

Cannabis-based products for pediatric epilepsy: A systematic review.

Epilepsia, 60(1), 6-19

Citation

Elliott, Jesse; DeJean, Deirdre; Clifford, Tammy; Coyle, Doug; Potter, Beth K; Skidmore, Becky; Alexander, Christine; Repetski, Alexander E; Shukla, Vijay; McCoy, Bláthnaid; Wells, George A. (2019). Cannabis-based products for pediatric epilepsy: A systematic review.. Epilepsia, 60(1), 6-19. https://doi.org/10.1111/epi.14608

Explore the wider topic